Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients

SIMPLE SUMMARY: Bruton’s tyrosine kinase inhibitor ibrutinib restores T-cell immunity and increases circulating T-cell numbers in chronic lymphocytic leukemia (CLL) patients. Recent evidence suggests T-cell enhanced expansion, rather than increased egress from secondary lymphoid organs (SLO), as a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateu-Albero, Tamara, Marcos-Jimenez, Ana, Wissmann, Stefanie, Loscertales, Javier, Terrón, Fernando, Stein, Jens V., Muñoz-Calleja, Cecilia, Cuesta-Mateos, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179528/
https://www.ncbi.nlm.nih.gov/pubmed/35681706
http://dx.doi.org/10.3390/cancers14112729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179528/
https://www.ncbi.nlm.nih.gov/pubmed/35681706
http://dx.doi.org/10.3390/cancers14112729

Ejemplares similares